Cheplapharm Medicines

from Wikipedia, the free encyclopedia
Cheplapharm Arzneimittel GmbH

logo
legal form GmbH
founding July 1998
Seat Greifswald , Germany
management Sebastian F. Braun, Bianca Y. Juha, Edeltraud Lafer, Jens Rothstein
Number of employees approx. 260 (2019)
sales 310 million euros (2018)
Branch pharmacy
Website www.cheplapharm.com

Company building in the Greifswald industrial park

The CHEPLAPHARM Arzneimittel GmbH (proper spelling CHEPLAPHARM) is a German company for "specialty pharmaceuticals", the world's brand medicines, food supplements, medical devices and cosmetics markets. The headquarters are in Greifswald in Mecklenburg-Western Pomerania. The subsidiaries are based in Hamburg , Levallois-Perret (France) and Englewood (New Jersey) , USA.

Cheplapharm has around 400 approvals in around 120 countries. Since it was founded in 1998, Cheplapharm has had double-digit annual growth rates thanks to a global “buy-and-build” strategy. The export share is around 96% of sales. Cheplapharm is part of Braun Beteiligungs GmbH .

history

The company was founded in 1998 by pharmaceutical manager Kurt Teubner in Freiburg . It was named after one of the first products in the range, the homeopathic diuretic Cheplaren. The Braun family bought the company in 2003 with an annual turnover of 600,000 euros, and the company's headquarters were relocated to Mesekenhagen . In the same year Sebastian F. Braun became managing director .

Since then, under the motto "Specialty pharma meets M&A competence", the company has acquired around 50 branded pharmaceuticals and medical products from German and international pharmaceutical companies (including Merck, Hoffmann-La Roche , Eli Lilly , Boehringer Ingelheim , Johnson & Johnson , AstraZeneca and Klosterfrau ). Important acquisitions were Distraneurin , a psychotropic drug that is used, among other things, to treat alcohol withdrawal symptoms , by AstraZeneca (2010), as well as the sleeping and sedative drug Rohypnol and the leukemia drug Vesanoid by Hoffmann-La Roche (2012). In addition to prescription drugs, well-known over-the-counter products such as Valerian Dispert (2009 from Vemedia), Thuringian arnica tincture (2011 from Klosterfrau) and Reisegold (2013 from Teva) were purchased.

2016 bought CHEPLAPHARM of Hoffmann-La Roche the rights for the benzodiazepine - antidote Anexate , for Antiadipositum Xenical and the beta-blocker carvedilol (Dilatrend for the acquisition took effect in January 2017 in force). According to the company, a total of 340 million euros was invested in these acquisitions this year.

In December 2017, the drug Calcivit D used against calcium and vitamin D deficiency was taken over from Hexal AG. In 2018, Cheplapharm acquired four preparations from F. Hoffmann-La Roche, including the antiviral drug Cymevene and the vitamin K preparation Konakion , the antiarrhythmic Sotalex / Sotacor from Bristol-Myers Squibb and the worldwide (except USA) rights to Visudyne from Novartis Drug used in the photodynamic therapy of wet age-related macular degeneration .

In 2008, Cheplapharm took over the pharmaceutical company Walter Ritter GmbH & Co., Hamburg, in 2012 the company Sanavita Pharmaceuticals, Werne, and in 2014 the US company Glenwood LCC, New York. The subsidiary Cheplapharm France SAS was founded in Levallois-Perret, France, in 2016.

The company now has a second headquarters in Greifswald and a logistics center in Riems . In 2018 the headquarters were relocated from Mesekenhagen to Greifswald.

Products

The portfolio includes prescription drugs for emergency medicine , addiction medicine , sleep medicine , urology , gastroenterology , hemato- oncology , cardiology , bariatric and ophthalmology, as well as over-the-counter drugs, care and medical products in pharmacies.

Awards

Winner of the Axia Best Managed Companies Award 2019

Web link

Individual evidence

  1. ↑ a b Greifswald pharmaceutical company Cheplapharm continues to grow . In: Ostseezeitung , January 16, 2019.
  2. ↑ Products
  3. ↑ Factsheet. (PDF) Cheplapharm, November 2018, accessed on February 6, 2019 .
  4. ↑ Bundesanzeiger search: Cheplapharm annual accounts. Federal Gazette, accessed on August 5, 2018 .
  5. ↑ Investor Presentation June 2018 (PDF) Cheplapharm, June 2018, accessed on August 5, 2018 .
  6. ↑ a b Cheplapharm remains on course for growth and complements its portfolio with four other products. Cheplapharm, January 26, 2018, accessed August 5, 2018 .
  7. ↑ The 100 largest companies in Mecklenburg-Western Pomerania. Nord / LB, December 14, 2015, accessed on November 15, 2016 .
  8. ↑ Cheplaren
  9. ↑ a b c d e At a glance. (PDF) Cheplapharm, December 2018, accessed on August 5, 2018 .
  10. ↑ Riemser reloaded
  11. ↑ Cheplapharm lands mega-deal in: Ostseezeitung, October 26, 2016
  12. ↑ Cornelia Meerkatz: Cheplapharm continues to grow. Ostsee-Zeitung, January 26, 2018, accessed on August 5, 2018 .
  13. ↑ Cheplapharm is expanding its portfolio with another cardiology product. Cheplapharm, May 8, 2018, accessed August 5, 2018 .
  14. ↑ Cheplapharm France
  15. ↑ New headquarters for Cheplapharm in: Ostseezeitung, March 12, 2014
  16. ↑ Cheplapharm therapeutic areas
  17. ↑ axiallent Best Managed Companies. WirtschaftsWoche , May 2019, accessed on November 1, 2019 (PDF; 5.2 MB).